Regulatory Issues of Platform Trials: Learnings from EU-PEARL

Area of Science:

• Clinical Trial Design
• Regulatory Science
• Patient-Centric Research

Background:

• Platform trials present numerous benefits for drug development and patient centricity.
• However, their complexity introduces significant methodological, regulatory, and ethical challenges.

Purpose of the Study:

• To address the complexities of platform trials within the EU Patient-Centric Clinical Trial Platforms (EU-PEARL) project.
• To review existing guidelines and gather stakeholder input to inform platform trial design.

Main Methods:

• Reviewed European Union and United States guidelines for platform trials.
• Engaged in regulatory interactions with the European Medicines Agency and US Food and Drug Administration.
• Collected stakeholder needs through workshops and dialogue with ethics committees, regulators, and health technology assessment bodies.

Main Results:

• Identified key methodological, regulatory, and ethical challenges associated with platform trials.
• Developed a master protocol template based on guideline review, regulatory feedback, and stakeholder input.
• Highlighted areas requiring further harmonization and research, including clinical trial submissions, multiplicity control, non-concurrent controls, and randomization schemes.

Conclusions:

• Master protocols are efficient for expediting drug development but require careful management of operational and regulatory complexities.
• Understanding and addressing diverse stakeholder requirements early is essential for successful platform trial implementation.
• Proactive dialogue with stakeholders and increasing regulatory guidance can further support the adoption of advanced clinical trial designs.